Imaging Heart Amyloid Deposits in Adults With Primary Amyloid Cardiomyopathy
Uses PET and MRI scans to view amyloid deposits in the heart of adults.
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Molecular Imaging of Primary Amyloid Cardiomyopathy
- Status
- Recruiting
- People taking part
- 171 people, planned
- Started
- 1 Apr 2016
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- F-18 florbetapir/C-11 acetate PET
- MRI
- N-13 ammonia PET
- Record updated
- 14 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with light chain amyloidosis, with or without heart involvement, to study heart amyloid deposits with imaging. Control groups with multiple myeloma or heart failure also take part.
- Age
- Older than 18 years (up to 99 years)
- Sex
- All sexes
- Disease stage
- Light chain amyloidosis confirmed by standard tests. Groups include active heart involvement, remission, early disease before heart involvement, and localized disease. Control groups have multiple myeloma or heart failure without amyloidosis.
- Earlier treatment
- For the remission group: complete or very good blood response for more than 1 year before enrolment.
- Biomarker or test result
- Active heart involvement group: abnormal troponin T (TnT) or abnormal age-adjusted NT-proBNP levels.
Main reasons for not taking part
- Unstable blood pressure or circulation, or heart failure that prevents lying flat for 1 hour
- Other non-amyloid heart disease such as valve disease or dilated cardiomyopathy
- Known coronary artery narrowing of more than 50% in any single territory
- Metal implants such as a pacemaker or ICD (except heart failure controls), or severe claustrophobia
- Dialysis, severe kidney problems, pregnancy, or allergy to F-18 florbetapir, C-11 acetate or gadolinium
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age > 18 years
- Diagnosis of light chain amyloidosis by standard criteria (immunofixation of serum and urine, IgG free light chain (FLC) assay, a biopsy of fat pad/ bone marrow, or organ biopsy, followed by typing of the light chain using immunohistochemistry or immunogold assay with confirmation by Mass spectroscopy as needed); For subjects traveling from out of town referred for systemic AL therapy based on clinical evaluation and laboratory testing, but, pending biopsy results, study enrollment and procedures may begin before official confirmation of biopsy results. If biopsy is negative for AL amyloidosis, subject will be considered a screen failure. There will be no more than 10 subjects who fall under this screen failure for the duration of the study; Subjects with localized amyloid deposition and non-systemic AL disease will be eligible for enrollment in group D
- Willing and able to provide consent
- Additional inclusion criteria for the Remission AL-CMP: Hematological response defined as complete hematological remission or very good partial response-differential free light chain (dFLC)<40 mg/dL for > 1 year prior to enrollment
- Additional inclusion criteria for the Active AL-CMP - exercise: Ability to perform supine bicycle exercise. Enrollment to this arm will stop after 36 subjects complete baseline and 6 months studies
- Additional inclusion criteria for the Active AL Pre-CMP - Normal left ventricular wall thickness (≤ 12 mm) and normal LVEF (≥55%) on echocardiography within 3 months or increased wall thickness with normal cardiac biomarker levels: not meeting above definition
- Additional inclusion criteria for Control Multiple Myeloma subjects: diagnosis of multiple myeloma without concomitant amyloidosis by standard criteria
- Additional inclusion criteria for Control Heart Failure subjects: diagnosis of heart failure without amyloidosis by standard criteria
- Additional inclusion criteria for the active AL-CMP: Abnormal TnT 5th generation levels (>9 ng/L: Female, >14 ng/L: Male) or abnormal age appropriate N terminal pro-brain natriuretic peptide, NT-proBNP (abnormal values: <50 years: >450 pg/ml; 50-75 years:>900 pg/ml; >75 years: >1800 pg/ml)
Who cannot take part
- Concomitant non-ischemic non-amyloid heart disease (valvular heart disease or dilated cardiomyopathy)
- Pregnant state. For women in child bearing age, a urine pregnancy test will be performed prior to the PET and the cardiac MRI studies
- Additional exclusion criteria for active AL Pre-CMP- Inability to return to BWH 12 month clinical evaluation; Additional exclusion criteria for microbiota study: Documented hypertrophic cardiomyopathy, HIV or chronic viral hepatitis, documented inflammatory bowel disease, systemic antibiotics, antivirals, antifungals or antiparasitic agents within 6 months, unable to mail the stool sample in a timely manner, bowel surgery, colon cancer, received chemotherapy, and pregnancy
- Decompensated heart failure (unable to lie flat for 1 hour)
- Known obstructive epicardial coronary artery disease with stenosis > 50% in any single territory
- Presence of MRI contraindications such as metallic implants (pacemaker or ICD) at the time of study enrollment except for Control Heart Failure subjects. Control HF subjects with no devices, or, with strictly MR compatible devices will be eligible to undergo MRI
- Documented allergy to F-18 florbetapir, C-11 acetate or gadolinium
- Significant renal dysfunction with estimated glomerular filtration rate < 30 ml/min/m2 within 14 days of each cardiac MRI study. Subjects who develop renal dysfunction over the course of the study, meeting criteria listed above, will be excluded from the cardiac MRI scan except for control HF subjects. These subjects with eGFR < 30 ml/min/1.73 m2 will undergo MRI without gadolinium contrast
- Hemodynamic instability
- Severe claustrophobia despite use of sedatives
- Subjects on dialysis will be excluded
- Additional exclusion criteria for the active AL-CMP subjects: Subjects unable to return to BWH for 6 and 12 month clinical evaluation
- Additional exclusion criteria for active AL-CMP-exercise subjects: Inability to exercise or return to BWH for C-11 acetate PET/CT at baseline and 6 month clinical evaluations
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in United States
- Brigham and Womens HospitalBoston, United StatesContact: Sharmila DorbalaTaking people
About the trial
What the trial wants to find out
Cardiac amyloidosis is a major cause of early treatment-related death and poor overall survival in individuals with systemic light chain amyloidosis. This project will develop a novel approach to visualize cardiac amyloid deposits using advanced imaging methods. The long-term goal of this work is to identify the mechanisms of cardiac dysfunction, in order to guide the development of novel life-saving treatments.
The 5 groups in the trial
- Active AL cardiac amyloidosisTreatment being tested
75 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of blood of the heart, as well as the heavy metal analysis of the blood at baseline, 6 months and 12 months after initiation of chemotherapy. 25 of these individuals will also undergo a N-13 ammonia PET scan of the heart following supine bicycle stress at baseline and at 6 months after initiation of chemotherapy.
Treatment: F-18 florbetapir/C-11 acetate PET, MRI, and N-13 ammonia PET
- Remission AL cardiac amyloidosisExisting treatment, for comparison
25 individuals with light chain systemic amyloidosis with cardiac involvement and plasma cell dyscrasia in hematological remission (complete hematological remission or very good partial response-differential free light chain (dFLC)\<40 mg/dL for \> 1 year prior to enrollment) will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI scan of the heart as well as a heavy metal analysis of the blood at baseline.
Treatment: F-18 florbetapir/C-11 acetate PET and MRI
- Active AL Pre-CMPTreatment being tested
36 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and without cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline. At 6 months they will undergo a research MRI of the heart and at 12 months they will have a clinical follow up. Subjects with contraindications to Cardiac MRI or gadolinium contrast may still be eligible for study participation.
Treatment: F-18 florbetapir/C-11 acetate PET and MRI
- Multiple Myeloma ControlsNo study treatment, for comparison
25 individuals with diagnosis of multiple myeloma without concomitant amyloidosis by standard criteria will undergo urine and blood testing only.
- Heart FailureTreatment being tested
10 individuals with diagnosis of heart failure without amyloidosis by standard criteria will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline..
Treatment: F-18 florbetapir/C-11 acetate PET and MRI
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Molecular Imaging of Primary Amyloid Cardiomyopathy
- Plain-language title
- Imaging Heart Amyloid Deposits in Adults With Primary Amyloid CardiomyopathyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT02641145, who can take part
- Publications
- Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.JACC. Cardiovascular imaging, 2025
- Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis.JACC. Cardiovascular imaging, 2024
- Mechanisms of left ventricular systolic dysfunction in light chain amyloidosis: a multiparametric cardiac MRI study.Frontiers in cardiovascular medicine, 2024
- Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy.JACC. Cardiovascular imaging, 2022
- Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease?JACC. Cardiovascular imaging, 2020
- Record updated
- 14 November 2025